Abstract
Purpose
To evaluate the potential effects of PEGylated pH-sensitive liposomes on the intracellular activity of a new peptide recently characterized as a novel inhibitor of the human thymidylate synthase (hTS) over-expressed in many drug-resistant human cancer cell lines.
Methods
Peptide-loaded pH-sensitive PEGylated (PpHL) and non-PEGylated liposomes (nPpHL) were carefully characterized and delivered to cis-platinum resistant ovarian cancer C13* cells; the influence of the PpHL on the drug intracellular activity was investigated by the Western Blot analysis of proteins involved in the pathway affected by hTS inhibition.
Results
Although PpHL and nPpHL showed different sizes, surface hydrophilicities and serum stabilities, both carriers entrapped the drug efficiently and stably demonstrating a pH dependent release; moreover, the different behavior against J774 macrophage cells confirmed the ability of PEGylation in protecting liposomes from the reticuloendothelial system. Comparable effects were instead observed against C13* cells and biochemical data by immunoblot analysis indicated that PEGylated pH-sensitive liposomes do not modify the proteomic profile of the cells, fully preserving the activity of the biomolecule.
Conclusion
PpHL can be considered as efficient delivery systems for the new promising anti-cancer peptide.
Similar content being viewed by others
Abbreviations
- [D-Gln4]LR:
-
New synthesized octapeptide (amminoacid sequence: LSCQLYQR) with inverted chirality at position 4 (corresponding to the amino acid glutamine) (LSCqLYQR)
- DHFR:
-
Dihydrofolate reductase
- EPR:
-
Enhanced permeation and retention
- HSP 90-alpha:
-
Heat shock protein (HSP90AA1)
- hTS:
-
Human thymidylate synthase
- nPpHL:
-
Non-PEGylated peptide-loaded pH-sensitive liposomes
- PBS:
-
Phosphate buffer solution
- PEG:
-
Poly-ethylene-glycol
- PpHL:
-
PEGylated peptide-loaded pH-sensitive liposomes
- RES:
-
Reticuloendothelial system
- TRAP1:
-
Tumour Necrosis Factor Receptor Associated Protein 1
References
Lian T, Ho RJ. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001;90:667–80.
Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93–102.
Scherphof GL, Dijkstra J, Spanjer HH, Derksen JTP, Uptake RFH. Intracellular processing of targeted and nontargeted liposomes by rat Kupffer cells in vivo and in Vitroa. Ann N Y Acad Sci. 1985;446:368–84.
Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28–51.
Abe K, Higashi K, Watabe K, Kobayashi A, Limwikrant W, Yamamoto K, et al. Effects of the PEG molecular weight of a PEG-lipid and cholesterol on PEG chain flexibility on liposome surfaces. Colloids Surf A Physicochem Eng Asp. 2015;474:63–70.
Hak S, Helgesen E, Hektoen HH, Huuse EM, Jarzyna PA, Mulder WJM, et al. The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging. ACS Nano. 2012;6:5648–58.
Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Long-Circ Drug Deliv Syst. 1995;16:285–94.
Xia Y, Tian J, Chen X. Effect of surface properties on liposomal siRNA delivery. Biomaterials. 2016;79:56–68.
Hatakeyama H, Akita H, Harashima H. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull. 2013;36:892–9.
Sacchetti F, D’Arca D, Genovese F, Pacifico S, Maretti E, Hanuskova M, et al. Conveying a newly designed hydrophilic anti-human thymidylate synthase peptide to cisplatin resistant cancer cells: are pH-sensitive liposomes more effective than conventional ones? Drug Dev Ind Pharm. 2017;43:465–73.
Cardinale D, Guaitoli G, Tondi D, Luciani R, Henrich S, Salo-Ahen OMH, et al. Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. Proc Natl Acad Sci U S A. 2011;108:E542–9.
Pelà M, Saxena P, Luciani R, Santucci M, Ferrari S, Marverti G, et al. Optimization of peptides that target human thymidylate synthase to inhibit ovarian Cancer cell growth. J Med Chem. 2014;57:1355–67.
Genovese F, Gualandi A, Taddia L, Marverti G, Pirondi S, Marraccini C, et al. Mass spectrometric/Bioinformatic identification of a protein subset that characterizes the cellular activity of anticancer peptides. J Proteome Res. 2014;13:5250–61.
Cheng Z, Al Zaki A, Hui JZ, Tsourkas A. Simultaneous quantification of tumor uptake for targeted and nontargeted liposomes and their encapsulated contents by ICPMS. Anal Chem. 2012;84:7578–82.
Lee KD, Nir S, Papahadjopoulos D. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry (Mosc). 1993;32:889–99.
Doktorovova S, Shegokar R, Martins-Lopes P, Silva AM, Lopes CM, Müller RH, et al. Modified rose Bengal assay for surface hydrophobicity evaluation of cationic solid lipid nanoparticles (cSLN). Eur J Pharm Sci. 2012;45:606–12.
Sacchetti F, Marraccini C, D’Arca D, Pelà M, Pinetti D, Maretti E, et al. Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery. Colloids Surf B: Biointerfaces. 2015;136:346–54.
DiSaia PJ, Sinkovics JG, Rutledge FN, Smith JP. Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors Am J Obstet Gynecol. 1972;114:979–89.
Andrews PA, Murphy MP, Howell SB. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res. 1985;45:6250–3.
Marverti G, Ligabue A, Paglietti G, Corona P, Piras S, Vitale G, et al. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells. Eur J Pharmacol. 2009;615:17–26.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–5.
Garbuzenko O, Barenholz Y, Priev A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids. 2005;135:117–29.
Allen C, Dos Santos N, Gallagher R, Chiu GNC, Shu Y, Li WM, et al. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep. 2002;22:225–50.
Miller CR, Bondurant B, McLean SD, McGovern KA, O’Brien DF. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry (Mosc). 1998;37:12875–83.
Martina M-S, Nicolas V, Wilhelm C, Ménager C, Barratt G, Lesieur S. The in vitro kinetics of the interactions between PEG-ylated magnetic-fluid-loaded liposomes and macrophages. Biomaterials. 2007;28:4143–53.
Yang C, Liu HZ, Fu ZX, Lu WD. Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma. BMC Biotechnol. 2011;11:21.
Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1:297–315.
Ponterini G, Martello A, Pavesi G, Lauriola A, Luciani R, Santucci M, et al. Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology. 2016;6:27198.
Taddia L, D’Arca D, Ferrari S, Marraccini C, Severi L, Ponterini G, et al. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: novel strategies to overcome cancer chemoresistance. Drug Resist Updat. 2015;23:20–54.
Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3–6.
de Carvalho Maroni L, de Oliveira Silveira AC, Leite EA, Melo MM, de Carvalho Ribeiro AF, Cassali GD, et al. Antitumor effectiveness and toxicity of cisplatin-loaded long-circulating and pH-sensitive liposomes against Ehrlich ascitic tumor. Exp Biol Med Maywood NJ. 2012;237:973–84.
Israelachvili JN. Intermolecular and Surface forces; ch. 17. 2nd Edition. London: Academic Press; 1991.
Wang R, Xiao R, Zeng Z, Xu L, Wang J. Application of poly(ethylene glycol)-distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives as nanomaterials in drug delivery. Int J Nanomedicine. 2012;7:4185–98.
Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov AA, Trubetskoy VS, Herron JN, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta. 1994;1195:11–20.
Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A. 2008;105:14265–70.
Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012;7:779–86.
Kharazian B, Hadipour NL, Ejtehadi MR. Understanding the nanoparticle-protein corona complexes using computational and experimental methods. Int J Biochem Cell Biol. 2016;75:162–74.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
ESM 1
(DOCX 16 kb)
Rights and permissions
About this article
Cite this article
Sacchetti, F., Marverti, G., D’Arca, D. et al. pH-Promoted Release of a Novel Anti-Tumour Peptide by “Stealth” Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells. Pharm Res 35, 206 (2018). https://doi.org/10.1007/s11095-018-2489-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11095-018-2489-z